IMPORTANT DISCLAIMER: Blank Capital Research ("BCR") is a technology platform, not a registered investment advisor or broker-dealer. The algorithmically generated signals, scores, and rankings provided on this site ("God Mode" Signals) are for informational and research purposes only and do not constitute financial advice, investment recommendations, or an offer to sell or solicit an offer to buy any securities.
HYPOTHETICAL PERFORMANCE RESULTS: The "timing scores" and "regime signals" displayed are based on quantitative models. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under-or-over compensated for the impact, if any, of certain market factors, such as lack of liquidity.
RISK OF LOSS: Trading in financial markets involves a high degree of risk and may result in the loss of your entire investment. Data provided by third-party sources (Intrinio, Snowflake) is believed to be reliable but is not guaranteed for accuracy or completeness. Past performance is not indicative of future results.
© 2026 Blank Capital Research. All rights reserved. System Version: Aegis V8 (God Mode).
Verdict
Quantitative factor alignment verified for current market regime.
Quant Score
Rank
#3692
Positioning
Market Dominance
Manufacturing
Pharmaceutical Products
$5.9B
Samarth Kulkarni
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases. The company's lead product candidate is CTX001, an ex-viggered therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies.
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
| Stock | Rating | Score▼ | Quality | Value | Momentum | P/E | EV/EBITDA | ROE | ROA | Gross Mgn | Op Mgn | Net Mgn | Rev Growth | Div Yield | D/E | Mkt Cap | AUDIT |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
$UL UNILEVER PLC | 78 | 96 | 98 | 59 | - | - | 28.5% | 8.0% | 100.0% | 100.0% | 10.4% | -4.6% | 3.3% | 0.0x | $141.8B | VS | |
$ASML ASML HOLDING NV | 77 | 89 | 86 | 83 | - | - | 46.1% | 16.6% | 51.3% | 31.9% | 26.8% | -4.0% | 1.0% | 25.0x | $272.1B | VS | |
$ESLT ELBIT SYSTEMS LTD | 76 | 81 | 87 | 85 | - | - | 10.3% | 3.1% | 24.1% | 7.2% | 4.7% | 14.3% | 0.8% | 25.0x | $11.4B | VS | |
$MT ArcelorMittal | 75 | 71 | 98 | 85 | - | - | 2.2% | 1.5% | 9.3% | 5.3% | 2.2% | -8.5% | 2.2% | 16.0x | $18.9B | VS | |
$AMAT APPLIED MATERIALS INC /DE | 75 | 85 | 87 | 84 | 20.9x | 13.6x | 35.5% | 19.8% | 48.7% | 29.2% | 24.7% | 4.4% | 0.8% | 32.0x | $181.9B | VS | |
$SIMO Silicon Motion Technology CORP | 75 | 84 | 86 | 85 | - | - | 11.8% | 8.8% | 45.9% | 11.3% | 11.1% | 25.7% | 3.7% | 0.0x | $1.8B | VS | |
$CODA Coda Octopus Group, Inc. | 74 | 83 | 90 | 79 | 16.3x | 11.9x | 7.6% | 7.0% | 66.5% | 17.1% | 15.6% | 39.0% | 0.0% | 0.0x | $115M | VS | |
$GSK GSK plc | 74 | 84 | 90 | 70 | - | - | 22.6% | 4.9% | 71.2% | 12.8% | 9.4% | 1.7% | 5.9% | 124.0x | $72.1B | VS | |
$EFXT Enerflex Ltd. | 74 | 80 | 91 | 83 | - | - | 3.0% | 1.1% | 20.9% | 7.3% | 1.3% | 3.0% | 0.9% | 67.0x | $1.2B | VS | |
$BUD Anheuser-Busch InBev SA/NV | 74 | 84 | 97 | 63 | - | - | 8.2% | 3.5% | 55.3% | 25.9% | 12.4% | 0.7% | 1.7% | 0.0x | $87.0B | VS | |
$CRSP CRISPR Therapeutics AG | 39 | 39 | 44 | 47 | - | - | -27.9% | -23.7% | 100.0% | -19004.2% | -16337.8% | 72.0% | 0.0% | 18.0x | $5.9B | ||
| SECTOR BENCH | - | - | - | - | - | 22.3x | 11.5x | -2.5% | -0.1% | 42.5% | 1.3% | -0.2% | 5.9% | 0.0% | 0.2x | - | REF |
CRISPR Therapeutics AG (CRSP) receives a "Avoid" rating with a composite score of 38.8/100. It ranks #3692 out of 7,333 stocks in our coverage universe and carries a 1-star rating. Ratings are driven by a 6-factor quantitative model measuring quality, value, momentum, investment, stability, and short interest.
Sign in to join the discussion.
YOY expansion rate
Core pricing power
Operating efficiency
Bottom-line conversion
Equity capital efficiency
Asset base utilization
Financial leverage load
Direct cash return
Samarth Kulkarni
Chief Executive Officer
Labor Force
460
39
23
49
Audit Verdict: Lower quality and stability scores may indicate governance concerns.
No recent insider transactions available for CRSP
In-line with peers — no strong momentum signal
Fair valuation relative to peers
Average quality profile
Average volatility — neutral timing signal
Aggressive spending — empire-building risk, dilutive growth
Below-average composite — caution warranted
Get full access to institutional-quality research tools with Blank Capital Pro.
Upgrade to ProStarting at $19.99/mo
Relative valuation derived from Manufacturing sector benchmarks. Model weights: EV/EBITDA (40%), P/B (35%), P/S (25%). Re-calculated daily.
No analyst ratings for CRSP.
View All RatingsMaterial decline in asset turnover efficiency detected
High margin volatility — erratic forensic earnings quality
ROE proxy -27.9% (sector -2.5%)
GM 100% vs sector 43%, OM -19004% vs sector 1%
Capital turnover N/A, R&D intensity 8114.1%
Rev growth 72%, 10yr history
Interest coverage N/A
Composite assessment of profitability, capital efficiency, and financial strength. Top-tier entities demonstrate sustainable cash flow generation and elite competitive moats.
Profit generated per dollar of shareholder equity
Efficiency of asset utilization
Pricing power and cost efficiency
Core business profitability
Bottom-line profitability
The Quality factor evaluates the persistence and magnitude of realized cash flows. Companies with scores >70 exhibit superior pricing power and structural financial resilience through diverse economic regimes.
Our uncertainty rating tracks the predictability of future cash flows and potential for permanent capital loss. Moderate visibility with standard industry cyclicality.
Our quantitative model flags CRISPR Therapeutics AG with an Avoid rating, assigning a composite score of 38.8/100 and 1 out of 5 stars. Ranked #3692 of 7,333 stocks, CRSP falls in the bottom tier across key factors. Historically, stocks with this profile have faced elevated risk of underperformance and capital loss.
CRSP's quality score of 39/100 is below average, suggesting challenges with profitability or capital efficiency. The company reports a return on equity of -27.9% (sector avg: -2.5%), gross margins of 100.0% (sector avg: 42.5%), net margins of -16337.8% (sector avg: -0.2%). Investors should examine whether management is actively addressing these weaknesses or if they reflect structural industry headwinds.
With a value score of 44/100, CRSP appears somewhat expensive relative to its fundamentals. Key valuation metrics include a P/B ratio of 2.67x. Investors paying a premium here are likely betting on above-average growth or margin expansion to justify current prices.
CRISPR Therapeutics AG's investment score of 23/100 suggests limited reinvestment activity. Key growth metrics include revenue growth of 72.0% vs. a sector average of 5.9% and a return on assets of -23.7% (sector: -0.1%). While this can be positive for mature, cash-generative businesses returning capital to shareholders, it may also signal a lack of growth opportunities or management conservatism.
CRSP is currently showing below-average momentum at 47/100, which may indicate weakening institutional interest or negative sentiment shifts. Revenue growth stands at 72.0% year-over-year, while a beta of 1.27 reflects its sensitivity to broader market moves. Investors should note that declining momentum can precede further price weakness, though contrarian opportunities sometimes emerge at these levels.
With a stability score of 49/100, CRSP exhibits average financial resilience. Key stability metrics include a beta of 1.27 and a debt-to-equity ratio of 18.00x (sector avg: 0.2x). While the balance sheet is not a major concern, the stock is subject to typical market volatility and may experience sharper drawdowns during risk-off episodes.
CRISPR Therapeutics AG's short interest score of 24/100 reveals significant bearish positioning, suggesting institutional investors are actively betting against the stock. Specific risk factors include above-average market sensitivity (beta: 1.27), elevated leverage (D/E: 18.00x). At $5.9B (mid-cap), CRSP carries meaningful risk and is best suited for investors with high risk tolerance who have thoroughly evaluated the bear thesis.
CRISPR Therapeutics AG is a mid-cap company in the Manufacturing sector, ranked #0 of 50 in its sector (100th percentile) and #3692 of 7,333 overall (50th percentile). Key comparisons include ROE of -27.9% trailing the -2.5% sector median and operating margins of -19004.2% below the 1.3% sector average. This top-quartile standing reflects exceptional competitive strength relative to Manufacturing peers.
While CRSP currently exhibits a AVOID profile, superior opportunities exist within the MANUFACTURING sector. Our model identifies several "Strong Buy" candidates with higher quality scores and more attractive valuations among direct industry competitors.
View Top Manufacturing Alpha →Quant Factor Profile
Upgrade catalyst
Improvement in Investment (23) would have the largest impact on the composite score.
ROE 1027% ABOVE SECTOR MEDIAN (FAVORABLE)
Gross Margin 135% ABOVE SECTOR MEDIAN (FAVORABLE)
Op. Margin 1473290% BELOW SECTOR MEDIAN
AUDIT DATA AS OF SEP 30, 2025 (Q2 FY2025)
We rate CRISPR Therapeutics AG (CRSP) as Avoid with a composite score of 38.8/100 at a current price of $56.60. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.
The rating is primarily driven by strength in stability (49th percentile) and momentum (47th percentile), which together account for the majority of the composite score. Offsetting weakness in investment (23th percentile) and quality (39th percentile) tempers our overall conviction. We assign a No Moat rating (39/100), High uncertainty, and Poor capital allocation.
Key items to watch: sustainability of the current growth rate; the path to profitability. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.
CRISPR Therapeutics AG holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 38.8/100 places it at rank #3692 in our full 7,333-stock universe. At $5.9B in market capitalization, CRISPR Therapeutics AG is a mid-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.
Revenue is growing at 72%, though momentum at the 47th percentile suggests the market has not yet fully recognized this trajectory. This potential disconnect between fundamental improvement and market recognition could represent an opportunity for patient investors if the growth trend persists.
The margin cascade tells an important story: gross margins of 100% (+57.5pp vs sector) narrow to operating margins of -19004% (-19005.4pp vs sector) and net margins of -16337.8%, yielding a gross-to-net conversion rate of -16338%. The significant margin erosion from gross to net suggests elevated operating expenses, high interest costs, or other structural drags that warrant monitoring.
At a current price of $56.60, CRISPR Therapeutics AG is trading near fair value based on current fundamentals. Our value factor score of 44/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. Valuation metrics are mixed, with no strong signal of mispricing in either direction.
The stock currently trades at P/B of 2.7x, P/S of 1579.9x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.
Gross margins of 100% signal strong pricing power and brand/IP advantages — businesses with margins above 40% have historically demonstrated more resilient earnings through economic cycles.
Revenue growth of 72% confirms the business is expanding its addressable market — growth at this level typically supports multiple expansion and attracts institutional capital.
A conservative balance sheet (18% D/E) provides financial flexibility for acquisitions, buybacks, or weathering economic downturns without dilution.
The Avoid rating (composite 38.8/100) reflects multi-factor weakness, and historically, stocks in this scoring range have underperformed the market by a meaningful margin.
Thin net margins of -16337.8% provide limited cushion against cost pressures, competitive pricing, or macroeconomic headwinds — even small changes in costs could swing the company to a loss.
We assign a High uncertainty rating to CRISPR Therapeutics AG. Key risk factors include current negative profitability (net margin -16337.8%). The wide range of potential outcomes widens our fair value estimate and increases the possibility of permanent capital impairment. Investors considering this name should size positions accordingly and demand a meaningful margin of safety before initiating.
Specific risk factors that inform our assessment include: current negative profitability (net margin -16337.8%). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 49th percentile and quality factor at the 39th percentile provide a quantitative summary of the overall risk landscape.
Key risk mitigants include: healthy gross margins of 100% provide a buffer against cost pressures; conservative leverage (18% D/E) limits balance sheet risk. These factors partially offset the identified risks and provide downside protection in adverse scenarios. On balance, the risk-reward profile warrants caution and disciplined position management.
We rate CRISPR Therapeutics AG's capital allocation as Poor. Key concerns include low returns on equity (-27.9%), negative profitability, weak asset returns (ROA -23.7%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — CRISPR Therapeutics AG significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.
Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.
In summary, CRISPR Therapeutics AG receives a Avoid rating with a composite score of 38.8/100 (rank #3692 of 7,333). Our quantitative framework assigns a No Moat (39/100, trend: stable), High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 40/100.
Our analysis does not support a constructive view on CRISPR Therapeutics AG at this time. The combination of limited competitive advantages, high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.
Analysis derived from Blank Capital Research quantitative terminal. For informational purposes only. No trade solicitation. Past performance not indicative of future results. Consult a qualified advisor.
We do not assign CRISPR Therapeutics AG a meaningful economic moat, scoring 39/100 on our composite assessment. Current fundamentals do not demonstrate the kind of durable competitive advantages — such as superior returns on invested capital, margin superiority, or reinvestment efficiency — that would protect the company from competitive erosion over the long term. The highest-scoring pillar, margin superiority, reached only 12.9/20.
The strongest moat sources are margin superiority (12.9/20) and growth durability (9.5/20). GM 100% vs sector 43%, OM -19004% vs sector 1%. Rev growth 72%, 10yr history. These pillars form the core of CRISPR Therapeutics AG's competitive identity and are the primary drivers of excess returns in our framework.
Areas of relative weakness include economic value creation (2.7/20) and reinvestment efficiency (7/20). ROE proxy -27.9% (sector -2.5%). Improvement in these areas could meaningfully widen the moat over time, while deterioration would be an early warning of competitive erosion.
Our moat trend assessment is Stable. Multi-year ROIC and operating margin trajectories show neither meaningful improvement nor deterioration, suggesting the competitive position is steady. We expect CRISPR Therapeutics AG's moat profile to remain largely unchanged absent a material shift in return on capital or industry dynamics.
Key profit drivers include gross margins of 100% providing a solid profitability foundation, robust top-line growth of 72% expanding the revenue base. The margin cascade from 100% gross to -19004% operating to -16337.8% net reveals the company's cost structure and reinvestment intensity. Our analysis indicates that profit quality raises some durability concerns, with the quality factor at the 39th percentile.
The margin profile shows gross margins of 100%, operating margins of -19004%, net margins of -16337.8%. Return metrics include ROE of -27.9% and ROA of -23.7%. Relative to the Manufacturing sector, gross margins are 57.5 percentage points above the sector median of 43%, and ROE of -27.9% compares to a sector median of -2.5%.
The balance sheet reflects a conservatively managed balance sheet with D/E of 18%, revenue growth of 72%. The sector median D/E is 0%, putting CRISPR Therapeutics AG at higher leverage than the typical peer. Overall balance sheet health is adequate for the current business environment.
Above 50MA
37.18%
Net New Highs
+51081
CRISPR Therapeutics AG, a major holding in Cathie Wood's ARK funds, faces significant headwinds as its momentum score plummeted from 76.81 to 50.97 following a 10% stock decline. The decline was triggered by CEO insider share sales exceeding 90,000 shares and disappointing Q3 revenue of just $890,000, far below the $8.06 million consensus estimate, signaling weak product adoption.
CRISPR Therapeutics has achieved a major milestone with Casgevy, the first CRISPR gene-editing therapy approved for rare blood diseases. The company has several promising pipeline candidates including zugo-cel for cancers and autoimmune diseases, CTX310 for cholesterol management, and SRSD107 as a next-gen anticoagulant. While the biotech's platform shows significant potential to revolutionize treatment standards, success depends on clinical execution. The analyst believes the company is more likely to be acquired than go to zero, making it suitable for volatility-tolerant investors.
CRISPR Therapeutics is highlighted as a promising biotech investment for 2026. The company's CRISPR-based gene-editing treatment Casgevy received FDA approval for blood disorders and has multi-billion-dollar potential. Multiple clinical trial updates and new trial launches are expected throughout 2026, which could serve as catalysts for stock growth.
CRISPR Therapeutics is positioned as an alternative investment to AI stocks, leveraging gene-editing technology to develop therapies for hard-to-treat diseases including Type 1 diabetes, anticoagulation disorders, and high cholesterol. While the company offers significant upside potential with its pipeline candidates and approved Casgevy medicine, it carries clinical and regulatory risks typical of early-stage biotech companies.
The article recommends three growth stocks for long-term investors: Amazon, leveraging AWS profitability and expanding AI/advertising segments; Vertex Pharmaceuticals, with a strong cystic fibrosis franchise and promising late-stage drug candidates; and TJX Companies, thriving with its off-price retail model and expansion plans. All three are positioned for sustained growth into the 2030s.